JP2019534322A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534322A5 JP2019534322A5 JP2019538093A JP2019538093A JP2019534322A5 JP 2019534322 A5 JP2019534322 A5 JP 2019534322A5 JP 2019538093 A JP2019538093 A JP 2019538093A JP 2019538093 A JP2019538093 A JP 2019538093A JP 2019534322 A5 JP2019534322 A5 JP 2019534322A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- immunostimulant
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399976P | 2016-09-26 | 2016-09-26 | |
| US62/399,976 | 2016-09-26 | ||
| PCT/US2017/053496 WO2018058123A1 (en) | 2016-09-26 | 2017-09-26 | Methods of treating tim-3 elevation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534322A JP2019534322A (ja) | 2019-11-28 |
| JP2019534322A5 true JP2019534322A5 (https=) | 2021-05-06 |
Family
ID=61691113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538093A Pending JP2019534322A (ja) | 2016-09-26 | 2017-09-26 | Ｔｉｍ−３の上昇を処置する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210369837A1 (https=) |
| EP (1) | EP3515486A4 (https=) |
| JP (1) | JP2019534322A (https=) |
| KR (1) | KR20190059304A (https=) |
| CN (1) | CN109937051A (https=) |
| CA (1) | CA3037253A1 (https=) |
| IL (1) | IL265568A (https=) |
| MX (1) | MX2019003314A (https=) |
| WO (1) | WO2018058123A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109757103B (zh) | 2016-07-14 | 2024-01-02 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
| AU2020224164A1 (en) * | 2019-02-22 | 2022-02-10 | Candel Therapeutics, Inc. | GMCI and DDRI combination therapy for treating cancer |
| EP4037705A4 (en) * | 2019-09-30 | 2024-02-21 | Candel Therapeutics, Inc. | Combination gmci and atri cancer treatment |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US20060120995A1 (en) * | 2004-12-02 | 2006-06-08 | Shah Maulik R | Neoadjuvant genetic compositions and methods |
| AU2014319921A1 (en) * | 2013-09-11 | 2016-03-17 | Compugen Ltd. | Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| SG11201705844SA (en) * | 2015-02-06 | 2017-08-30 | Heat Biologics Inc | Vector co-expressing vaccine and costimulatory molecules |
-
2017
- 2017-09-26 MX MX2019003314A patent/MX2019003314A/es unknown
- 2017-09-26 JP JP2019538093A patent/JP2019534322A/ja active Pending
- 2017-09-26 KR KR1020197011865A patent/KR20190059304A/ko not_active Ceased
- 2017-09-26 WO PCT/US2017/053496 patent/WO2018058123A1/en not_active Ceased
- 2017-09-26 US US16/336,207 patent/US20210369837A1/en not_active Abandoned
- 2017-09-26 CN CN201780069200.4A patent/CN109937051A/zh active Pending
- 2017-09-26 EP EP17854134.8A patent/EP3515486A4/en not_active Withdrawn
- 2017-09-26 CA CA3037253A patent/CA3037253A1/en not_active Abandoned
-
2019
- 2019-03-24 IL IL265568A patent/IL265568A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Type I interferon-mediated tumor immunity and its role in immunotherapy | |
| Wang et al. | Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy | |
| Wang et al. | Therapeutic strategies to remodel immunologically cold tumors | |
| Grigg et al. | Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers | |
| Moschella et al. | Combination strategies for enhancing the efficacy of immunotherapy in cancer patients | |
| Garbe et al. | Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting | |
| Drozdzik et al. | Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma | |
| Wang et al. | Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia | |
| JP2020510624A5 (https=) | ||
| Deng et al. | Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9 | |
| JP2019534322A5 (https=) | ||
| Pilla et al. | Methods for improving the immunogenicity and efficacy of cancer vaccines | |
| Haddad et al. | Using viral vectors to deliver local immunotherapy to glioblastoma | |
| Kohlmeyer et al. | Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy | |
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| Wang et al. | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? | |
| Chen et al. | Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence | |
| Huang et al. | Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines | |
| Chen et al. | Inhibition of mouse RM-1 prostate cancer and B16F10 melanoma by the fusion protein of HSP65 & STEAP1 186-193 | |
| Pol et al. | Oncolytic viruses: a step into cancer immunotherapy | |
| Lee et al. | Precision medicine-enabled cancer immunotherapy | |
| Indrová et al. | Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I− tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines | |
| Basso et al. | T cell therapy for nasopharyngeal carcinoma | |
| US20110014241A1 (en) | Therapeutic Cancer Antigens | |
| Guida et al. | Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? |